URB2 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 1.69710000497147E-08 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.67120000005294E-06 |
Normal-vs-Stage2 |
1.122100E-02 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
3.215700E-02 |
Stage1-vs-Stage2 |
9.733400E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
5.958400E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
6.052200E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
3.37729999966285E-07 |
Normal-vs-AfricanAmerican |
3.76859999999812E-05 |
Normal-vs-Asian |
2.190700E-04 |
Caucasian-vs-AfricanAmerican |
6.253000E-01 |
Caucasian-vs-Asian |
7.722200E-01 |
AfricanAmerican-vs-Asian |
1.785160E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
1.151810E-04 |
Normal-vs-Female |
4.14120000000739E-05 |
Male-vs-Female |
4.735000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
2.478500E-02 |
Normal-vs-Extreme_Weight |
2.789300E-04 |
Normal-vs-Obese |
4.400300E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
6.916600E-01 |
Normal_Weight-vs-Obese |
2.554400E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
3.682800E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
5.61639999999697E-05 |
Normal-vs-Age(41-60Yrs) |
1.183630E-03 |
Normal-vs-Age(61-80Yrs) |
4.33480000000541E-05 |
Normal-vs-Age(81-100Yrs) |
3.419800E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.562170E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.668400E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.747200E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.123600E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.013800E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.516600E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
8.080800E-01 |
Normal-vs-Grade 3 |
6.782800E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
9.709800E-01 |
Grade 2-vs-Grade 4 |
8.080800E-01 |
Grade 3-vs-Grade 4 |
6.782800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
9.73819999972036E-07 |
Normal-vs-N1 |
2.652100E-02 |
N0-vs-N1 |
6.068300E-02 |
|
|